FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...

On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...

The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...

A U.S. Food and Drug Administration (FDA) advisory committee is meeting in July to consider loosening restrictions around ...

In April, FDA detailed its priorities for drug compounding in 2019, which include issuing a new proposed rule to update the list of bulk drug substances that can be used in compounding under Section ...

Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and Drug Administration (FDA) goes through with its plan to remove the three ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...